Ultragenyx Pharmaceuticals Advances Clinical Development of UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)

Published: May 15, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NOVATO, Calif., May 15, 2013 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced a Phase 1/2 study of UX003 for mucopolysaccharidosis type 7 (MPS 7, or Sly Syndrome). UX003 is a recombinant human b-glucuronidase intended as an enzyme replacement therapy (ERT) for the treatment of MPS 7, an extremely rare autosomal recessive lysosomal storage disorder characterized by a deficiency of the lysosomal enzyme b-glucuronidase and a severe multi-system disease. MPS 7 has no approved therapies.

Help employers find you! Check out all the jobs and post your resume.

Back to news